Skye Bioscience appoints Dr. Deborah Charych to Board of Directors; director Rai resigns

Skye Bioscience, Inc.

Bobby Rai resigned from Board and Nominating Committee effective Feb 14, 2023; not due to any disagreement.
Dr. Deborah Charych elected to fill the vacancy; will receive $40,000 annual cash compensation.
Charych granted options to purchase 250,000 shares, vesting monthly over one year.
Charych co-founded RayzeBio, led R&D strategy raising $418M; previously led Nektar deal with Bristol Myers for $1.8B.
Her background includes GPCR and cannabinoid receptor biology, relevant to Skye's glaucoma drug development.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bobby Rai

Director

SKYE · Skye Bioscience, Inc.

Effective: 2023-02-14
Successor: Deborah Charych
Filed: February 16, 2023, 6:59 PM ET

On February 14, 2023, Bobby Rai resigned as a member of the Board of Directors (the "Board") of Skye Bioscience, Inc. (the "Company") and the Nominating and Corporate Governance Committee of the Board.

Appointed

Deborah Charych

Director

SKYE · Skye Bioscience, Inc.

Effective: 2023-02-14
Filed: February 16, 2023, 6:59 PM ET

On February 14, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Dr. Deborah Charych, Ph.D. to fill the vacancy created by Mr. Rai's resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bobby Rai resigned as Director at Skye Bioscience, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 14, 2023, Bobby Rai resigned as a member of the Board of Directors (the "Board") of Skye Bioscience, Inc. (the "Company") and the Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Deborah Charych was elected as Director at Skye Bioscience, Inc..

Action: elected
Role: Director

Exact text from the filing

On February 14, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Dr. Deborah Charych, Ph.D. to fill the vacancy created by Mr. Rai's resignation.

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.